Posts in category Healthcare

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Generic Drug Pricing Not Getting Worse, But Ghost of Headwinds Remain

David Steinberg is out with a cautious note on Teva, believing much of the outlook is priced into the stock.

Marinus Pharmaceuticals Inc (MRNS) Wins a Bull Thanks to Potential in Multiple Central Nervous System Indications

Mizuho’s Difei Yang approaches the biotech player as a new bull, angling for a whopping 204% in return potential for MRNS shares.

Arena Pharmaceuticals, Inc. (ARNAׁ) Stock Has More Upside Ahead: Cantor

It’s a big day for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The drug maker released impressive results …

Top Analyst Bullish on Adaptimmune Therapeutics PLC – ADR (ADAP) “Major” Share Drivers Set to Hit This Year

Cowen’s Eric Schmidt gives a vote of confidence to ADAP on back of yesterday’s fourth quarter financial and pipeline update.

Valeant Pharmaceuticals Intl Inc (VRX): Organic Growth Comeback Not There Yet

H.C. Wainwright’s Ram Selvaraju is glad to see VRX pushing out maturities on its massive debt- but still sees a “rock” rolling down the path.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Can Migraine Asset Still Secure “On-Time” FDA Approval?

Guggenheim’s Rohit Vanjani is reassured from the sidelines on TEVA’s fremanezumab’s prospects to clear an FDA not despite supply plant’s Warning Letter.

H.C. Wainwright Pounds the Table on Pieris Pharmaceuticals Inc (PIRS)

H.C. Wainwright’s Joseph Pantginis is enticed by various clinical irons in the fire for PIRS moving forward.

TherapeuticsMD Inc (TXMD): Mega Metamorphosis Ahead? This Analyst Says Yes

Oppenheimer’s Jay Olson is liking the setup of TXMD shares more and more amid major commercial potential.

Vascular Biogenics Ltd (VBLT) Loses a Bull Following Disappointing GLOBE Flop

H.C. Wainwright’s Swayampakula Ramakanth believes this failure now “casts doubt” on VBLT’s therapeutic prospects for its VB-111 asset.